Viemed Healthcare Inc (VMD) — Titan Protect Analysis

VMD

Viemed Healthcare Inc

Healthcare · ·

$9.97

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$361M

Total market value of the company

Trailing P/E

25.43

Premium valuation

Forward P/E

23.53

Based on estimated future earnings — lower means cheaper

Rev Growth

+27.5%

Year-over-year revenue change

Profit Margin

5.2%

How much profit the company keeps from each dollar of revenue

ROE

10.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+10% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Viemed Healthcare Inc

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and ren

https://www.viemed.com

Country: United States Employees: 1,387 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.546

Good returns relative to risk taken

Kelly Fraction

0.0116

Marginal edge — very small allocation suggested

Calmar Ratio

0.379

Drawdown risk outweighs the returns — higher risk profile

Annual Return

14.3%

Historical annualised return based on price data

Max Drawdown

-37.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.15

Moves slightly more than the broader market

52W High

$10.18

2% below the year high

52W Low

$5.93

68% above the year low

Avg Volume

304,444

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.37

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.53

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

57.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.3%

Profit from core operations before interest and tax

Free Cash Flow

$28M

Positive — the business generates more cash than it spends

Revenue (TTM)

$287M

Total revenue over the last 12 months

Net Income

$15M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$11.00

Target Median

$11.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go